Clinical Trials Logo

Thyroid Eye Disease clinical trials

View clinical trials related to Thyroid Eye Disease.

Filter by:
  • Not yet recruiting  
  • Page 1

NCT ID: NCT06413043 Not yet recruiting - Thyroid Eye Disease Clinical Trials

Study on Efficacy of Add on Selenium in Mild-to-moderate Graves Ophthalmopathy

Start date: May 6, 2024
Phase: N/A
Study type: Interventional

The Study on efficacy of add on selenium in mild-to-moderate Graves ophthalmopathy: A Randomized Control Trial.; The study aims to evaluate the response of adding selenium in patients with Graves ophthalmopathy, focusing on improving quality of life, CAS scoring, and thyroid status. The methodology involves a Randomized Control Trial with a sample size of 78 patients. Patients meeting specific criteria will receive either standard treatment with Anti Thyroid Drugs and Vitamin B complex or add on selenium with Vitamin B complex for 6 months. Outcome measures include CAS score reduction, thyroid function improvement, and quality of life enhancement. The study will last 18 months, with various investigations and ethical considerations outlined. The document emphasizes the importance of early diagnosis of Graves Ophthalmopathy to prevent vision loss and deformity, highlighting the significance of informed patients and healthcare professionals regarding TED symptoms and risk factors.

NCT ID: NCT06401044 Not yet recruiting - Thyroid Eye Disease Clinical Trials

A Study of AMG 732 in Healthy Participants and Participants With Thyroid Eye Disease

Start date: May 31, 2024
Phase: Phase 1
Study type: Interventional

The primary objective of this study is to investigate the safety and tolerability of AMG 732 after single subcutaneous (SC) doses.

NCT ID: NCT06384547 Not yet recruiting - Thyroid Eye Disease Clinical Trials

A Randomized, Active Controlled, Safety and Tolerability Study of VRDN-001 in Participants With Thyroid Eye Disease (TED)

Start date: April 2024
Phase: Phase 3
Study type: Interventional

The investigational drug, VRDN-001, is a monoclonal antibody that inhibits the activity of a cell surface receptor called insulin-like growth factor-1 receptor (IGF-1R). Inhibition of IGF-1R may help to reduce the inflammation and associated tissue swelling that occurs in patients with thyroid eye disease (TED). The primary objective of this clinical trial is to evaluate the safety and tolerability of VRDN-001 in patients with TED.

NCT ID: NCT06235372 Not yet recruiting - Thyroid Eye Disease Clinical Trials

Evaluation of the Corneal Endothelial Cell Layer by Specular Microscopy in Patients With Thyroid Eye Disease

Start date: March 21, 2024
Phase:
Study type: Observational

To investigate corneal endothelial cell layer damage by specular microscopy in patients with thyroid eye disease